A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185

Authors :: Jesús F. San-Miguel
Fredrik Schjesvold
Naoki Takezako
Lionel Karlin
Thierry Facon
Kenshi Suzuki
Robert Donald McCroskey
Jason J. Z. Liao
Robert M. Rifkin
Patricia Marinello
Razi Ghori
Sagar Lonial
Richard Leblanc
Saad Z. Usmani
Habte A. Yimer
Albert Oriol Rocafiguera
Michele Cavo
Sundar Jagannath
Mohammed Z.H. Farooqui
Source :: Journal of Clinical Oncology. 36:8010-8010
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 8010Background: KEYNOTE-185 (NCT02579863) evaluated Rd ± pembro in patients (pts) with newly diagnosed, ASCT-ineligible MM. Methods: Pts were randomized 1:1 to pembro (200 mg Q3W) + Rd (len 25 mg [...

Full Text Access

Tools